As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Editor's Pick: Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma
Despite the perceived negative health consequences of an ageing immune system, older cancer patients may actually respond better to checkpoint blockade immunotherapy. Wigand et al. looked at surgically-resected head and neck cancers and found that 70-90 year-old patients had significantly fewer regulatory T cells blocking the activity of CD8+ cytotoxic T cells (CTL) than younger patients, although both had equal amounts of CTL. This would make the elderly more likely to respond to the immune-boosting effects of immunotherapy.
COVID-19 and impact on peer review
Announcing the launch of In Review
Immunity & Ageing, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Nutrigerontology: a key for achieving successful ageing and longevity
Collection published: April/ May 2016
Cross journal collection
Day of Immunology 2015
Collection published: 28 April 2015
Positive biology: the centenarian lesson
Immunity & Ageing
Collection published: 23 April 2012
Aims and scope
Immunity & Ageing, published since 2004, is a specialist open access journal dedicated to increasing knowledge about the impact of ageing on immune systems, the influence of aged immune systems on organismal well-being and longevity, and the potential for interventions to increase lifespan. The journal welcomes submissions dealing with any aspect of ageing in human and model organisms that relates to immune function.
All articles undergo rapid and rigorous peer-review and all accepted articles are published open access to provide the highest visibility for authors’ work.
The increasing realization that immune ageing and organismal ageing are intimately inter-related puts the immune system centre-stage in our efforts to understand and manipulate the ageing process and Immunity & Ageing continues to offer a specialized conduit for dissemination of new knowledge in this increasingly important arena.
View the most shared articles across the past month
About the Editors
Graham Pawelec is Professor of Experimental Immunology at the University of Tübingen, Germany, where he led the Tübingen Ageing and Tumour Immunology (TATI) group from 1999 to 2017. He is currently affiliated with the Health Sciences North Research Institute of Canada, Sudbury, ON, and is a Visiting Professor at Nottingham Trent University, King´s College London, and Manchester University, UK. His research interests remain centered on immunogerontology in the context of cancer immunology and immunotherapy, and vaccination.
Nan-ping Weng is tenured senior investigator, Chief of Lymphocyte Differentiation Section, Laboratory of Molecular Biology and Immunology at the National Insitute on Aging (NIA), NIH. He joined the Laboratory of Immunology at the NIA as a tenure-track investigator in 1997 and has been tenured senior investigator since 2006. His laboratory focuses on the understanding of molecular and cellular mechanisms of T cell differentiation and age-associated decline of T cell functions.
Professor Calogero Caruso MD Professor of General Pathology and Director of Palermo University Medical School “Ippocrate”
Whether your interests are immunological aspects of ageing, age-related diseases and longevity, this journal can serve as an appropriate venue.
Annual Journal Metrics
53 days to first decision for reviewed manuscripts only
38 days to first decision for all manuscripts
122 days from submission to acceptance
24 days from acceptance to publication
139 Altmetric mentions